new glp 1 GLP-1 Weight Loss Drugs May Reduce Chance of Cancer Progressing, Study Finds New GLP-1 Outperforms Oral Semaglutide

Statin-associated muscular and renal adverse events: Data mining of the public version of the FDA adverse event reporting system

doi: 10.1111/dom.15058 46 YamadaYKatagiriHHamamotoYDeenadayalanSNavarriaANishijimaKet al

Considering the prolonged half-life of most GLP-1 agonists currently prescribed, it is unfeasible to withhold these agents for weeks prior to surgery to achieve normalisation of gastric function with unknown impact on aspiration rates, appreciating the detrimental effects of poorer glycaemic control on withholding these agents and associated higher risk of peri/postoperative complications (major cardiovascular events, poor wound healing, increased wound infection etc.)

Maximum Weight Loss Potential (Future) Amycretin Phase 1b/2a showed up to 24.3% weight loss at 36 weeks with no plateau, suggesting even greater loss with longer treatment

Nope, just science

Univariate analysis revealed that younger age was associated with an increased RGC risk ( p = 0.003), whereas colonoscopy performed on the same day exerted a protective effect against RGC ( p 150 mg/dL ( p = 0.002)